Endo Int'l (ENDP) Tops Q4 EPS by 9c; Guides FY16 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Remains Sidelined Following Endo Int'l's (ENDP) Mixed 4Q Results
March 2, 2016 7:10 AM ESTMizuho Securities reiterated a Neutral rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $42.00 (from $55.00), following the company's 4Q earnings report. ENDP reported revenues of $1.07B, in-line with consensus' estimate. EPS was reported at $1.36, ahead of expectations of $1.27. ENDP introduced... More
Piper Jaffray Remains Bullish on Endo Int'l (ENDP) Following an In-Line 4Q - PT to $81
March 1, 2016 9:04 AM ESTPiper Jaffray maintained an Overweight rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $81.00 (from $83.00), following the company's relatively in-line 4Q earnings results. Endo reported 4Q15 non-GAAP EPS of $1.36 on revenues of $1.1B. Sales of Xiaflex in 4Q15 were $50M, up 26% versus 3Q15 sales of $40M, with ENDP citing... More
Leerink Partners Cuts Price Target on Endo Int'l (ENDP) Following 4Q Earnings Report
March 1, 2016 7:50 AM ESTLeerink Partners maintained an Outperform rating on Endo International plc (NASDAQ: ENDP), and cut the price target to $51.00 (from $64.00), following the company's 4Q earnings report. ENDP generics were unfavorably impacted by increased pricing pressure in pain and commodity products within legacy Qualitest, an... More

